LACTOLOGY FOUNDATION

A07X Other Antidiarrheals: Toxicological and Lactological Monograph

ATC Class and General Pharmacology

The ATC group A07X — Other Antidiarrheals belongs to the broader A07 category, Antidiarrheals, intestinal anti-inflammatory and anti-infective agents, within the anatomical main group A, Alimentary tract and metabolism. The WHO ATC system groups medicinal substances according to their principal therapeutic use, target organ/system, and pharmacological or chemical properties.atcddd.fhi+1

A07X is a heterogeneous residual therapeutic subgroup that includes antidiarrhoeal agents which are not classified as intestinal anti-infectives, adsorbents, oral rehydration products, antimotility agents, intestinal anti-inflammatory agents, or antidiarrhoeal microorganisms. The subgroup includes pharmacologically diverse substances, such as locally acting tannin-containing products, mineral/calcium-based preparations, antisecretory agents, and plant-derived or biologically active products. Examples listed in the ATC index include albumin tannate, carob-derived preparations, calcium compounds, racecadotril, and crofelemer; however, individual agents require separate assessment because their pharmacology, indications, systemic exposure, and safety evidence differ substantially.

The therapeutic objective of A07X agents is symptomatic reduction of diarrhoea through one or more of the following broad mechanisms:

• Reduction of intestinal secretion of water and electrolytes.
• Enhancement of net intestinal fluid absorption.
• Local protection or modification of the intestinal mucosal surface.
• Astringent effects mediated by protein precipitation or mucosal surface interactions.
• Modulation of epithelial ion transport, including chloride secretion, in selected antisecretory products.
• Supportive reduction of stool liquidity without necessarily suppressing intestinal propulsion.

This class should not be considered pharmacologically uniform. In particular, some members act predominantly within the intestinal lumen and have minimal systemic bioavailability, whereas others may be absorbed to a clinically relevant extent. Therefore, the ATC designation A07X is useful for classification but cannot, by itself, establish pharmacokinetic equivalence or a common lactation risk category.

Toxicological Profile

The toxicological profile of A07X medicines is primarily determined by their chemical nature, degree of gastrointestinal absorption, dose, duration of administration, concomitant disease, and patient age. In general, many agents in this group are intended for short-term oral use and act locally in the gastrointestinal tract. This local action may limit systemic toxicity, but it does not eliminate the risk of clinically relevant adverse effects.

Potential toxicological concerns across the class include:

• Constipation, abdominal discomfort, nausea, bloating, or altered bowel habits due to reduced stool water content or modification of intestinal secretion.
• Dehydration or electrolyte imbalance when symptomatic treatment delays adequate oral rehydration, particularly in infants, older adults, and medically fragile patients.
• Hypersensitivity reactions to active ingredients, excipients, botanical components, or protein-containing products.
• Interference with the intestinal absorption of concomitant medicines, nutrients, or trace elements, depending on the product’s binding, coating, or astringent properties.
• Accumulation or systemic effects in patients with impaired renal, hepatic, or gastrointestinal function where absorption is increased or elimination is reduced.
• Product-specific concerns related to salts, minerals, botanical constituents, contaminants, or variable composition in non-standardised preparations.

Astringent and tannin-based products may produce local gastrointestinal effects through interaction with mucosal proteins. At excessive exposure, their effects on nutrient availability, gastrointestinal tolerance, and the absorption of other orally administered drugs may be clinically relevant. Mineral-containing preparations may require additional consideration in patients with renal impairment or in settings of prolonged/high-dose exposure, because systemic mineral handling is not always negligible.

Antisecretory substances may have a more targeted pharmacodynamic action on epithelial electrolyte transport. Although this can be therapeutically advantageous in secretory diarrhoea, clinical evaluation should consider the underlying cause of diarrhoea, the risk of dehydration, and whether symptom suppression could delay diagnosis or appropriate treatment of infectious, inflammatory, or other serious gastrointestinal disease.

A07X products should not replace oral rehydration therapy when clinically indicated. Antidiarrhoeal treatment is potentially inappropriate when diarrhoea is accompanied by high fever, bloody stools, severe abdominal pain, marked systemic toxicity, or suspected invasive infection, because the priority is etiological evaluation, hydration, and targeted management rather than symptomatic suppression alone.openstax+1

Lactation Pharmacology and Infant Exposure

Lactation risk assessment for A07X medicines must be substance-specific because the class contains agents with markedly different physicochemical and pharmacokinetic properties. The principal determinants of infant exposure through breast milk are maternal systemic absorption, plasma protein binding, molecular size, lipophilicity, ionisation, elimination half-life, active metabolites, oral bioavailability in the infant, and the maturity of the infant’s gastrointestinal, renal, and hepatic function.

For predominantly locally acting and minimally absorbed products, transfer into human milk is expected to be low because maternal plasma concentrations are negligible or absent. Even if trace amounts reach milk, oral absorption by the breastfed infant may remain limited for certain poorly bioavailable substances. This pharmacokinetic pattern generally supports a low theoretical exposure risk, particularly during brief maternal treatment.

However, “minimal absorption” should not automatically be interpreted as “no risk.” Important qualifications include:

• Absorption may increase in severe gastrointestinal inflammation, mucosal injury, altered permeability, overdose, or prolonged treatment.
• Products with variable composition, especially botanical or combination formulations, may have uncertain systemic exposure and insufficient lactation data.
• Mineral or salt-containing products may have a different exposure profile from non-absorbed luminal agents.
• Infant vulnerability is greatest in premature neonates, newborns in the first weeks of life, infants with renal or hepatic dysfunction, and infants with significant gastrointestinal disease.
• The clinical consequence of maternal diarrhoea itself may be important, as dehydration, infection, malnutrition, or impaired maternal capacity to breastfeed may affect lactation and infant care.

For systemic antisecretory agents within or associated with this subgroup, milk transfer cannot be predicted solely from class membership. Assessment should include the individual substance’s oral bioavailability, protein binding, molecular properties, metabolic pathways, and available human milk or infant-outcome data. Where direct lactation data are absent, a structured evidence-based assessment should distinguish between a low predicted milk concentration and a demonstrated absence of infant risk.

The breastfed infant should be monitored when maternal A07X treatment is clinically necessary, especially during repeated or prolonged administration. Relevant observations include changes in stool frequency or consistency, constipation, poor feeding, vomiting, abdominal distension, unusual irritability, lethargy, poor weight gain, and signs of dehydration. These effects are nonspecific but may indicate either direct infant exposure or an unrelated concurrent illness requiring clinical assessment.

Lactological Safety Assessment and Clinical Recommendations

A07X is best regarded as a heterogeneous, predominantly low-to-uncertain lactation-risk class, rather than as a class uniformly compatible or contraindicated during breastfeeding. Short-term use of a well-characterised, poorly absorbed, locally acting agent is often pharmacologically compatible with continued breastfeeding, provided that the maternal indication is appropriate and that adequate hydration is maintained. This conclusion is based principally on expected low maternal systemic exposure, not on a blanket safety assumption for every substance in the group.

Clinical management should follow a structured lactological approach:

1. Assess the cause and severity of maternal diarrhoea. Evaluate hydration status, fever, blood or mucus in stool, severe pain, recent antimicrobial exposure, travel, suspected foodborne disease, inflammatory bowel disease, and signs of systemic illness.
2. Prioritise oral rehydration and nutritional support. Rehydration is central to management of acute diarrhoea and is essential for maintaining maternal wellbeing and milk production. Antidiarrhoeal therapy is adjunctive, not a substitute for fluid and electrolyte replacement.
3. Select the lowest-risk individual product. Prefer a single-ingredient, standardised, locally acting medicine with low oral systemic bioavailability and a short intended treatment course. Avoid unnecessary multi-ingredient products, poorly characterised herbal preparations, and agents with uncertain composition or significant systemic absorption.
4. Use the lowest effective dose for the shortest necessary duration. Prolonged, repeated, or high-dose use should prompt reassessment of diagnosis, drug suitability, and infant exposure risk.
5. Continue breastfeeding when maternal clinical status permits. Acute uncomplicated diarrhoea alone is not usually a reason to interrupt breastfeeding. Maintaining breastfeeding supports infant nutrition and hydration, while maternal hand hygiene remains essential to reduce transmission of infectious pathogens.
6. Monitor the infant in higher-risk situations. Enhanced caution is appropriate for preterm infants, neonates, infants with chronic disease, and situations involving maternal use of a systemically absorbed or insufficiently characterised A07X agent.
7. Seek medical review when red flags occur. Maternal red flags include persistent symptoms, severe dehydration, high fever, blood in stool, severe abdominal pain, reduced urine output, suspected invasive infection, or inability to maintain oral intake. Infant red flags include poor feeding, fewer wet diapers, lethargy, fever, persistent vomiting, marked diarrhoea, or poor weight gain.

In toxicological-lactological terms, the key principle is that A07X classification does not replace agent-specific evaluation. The most favourable breastfeeding profile is generally expected for short-course therapy with a well-defined, minimally absorbed intestinal product; the greatest uncertainty applies to systemic, complex, combination, botanical, or poorly studied products. Individual monographs should therefore address each active substance separately, incorporating human milk data, infant outcomes, pharmacokinetics, formulation characteristics, and clinical indications.